<code id='799D0F7C68'></code><style id='799D0F7C68'></style>
    • <acronym id='799D0F7C68'></acronym>
      <center id='799D0F7C68'><center id='799D0F7C68'><tfoot id='799D0F7C68'></tfoot></center><abbr id='799D0F7C68'><dir id='799D0F7C68'><tfoot id='799D0F7C68'></tfoot><noframes id='799D0F7C68'>

    • <optgroup id='799D0F7C68'><strike id='799D0F7C68'><sup id='799D0F7C68'></sup></strike><code id='799D0F7C68'></code></optgroup>
        1. <b id='799D0F7C68'><label id='799D0F7C68'><select id='799D0F7C68'><dt id='799D0F7C68'><span id='799D0F7C68'></span></dt></select></label></b><u id='799D0F7C68'></u>
          <i id='799D0F7C68'><strike id='799D0F7C68'><tt id='799D0F7C68'><pre id='799D0F7C68'></pre></tt></strike></i>

          Home / comprehensive / focus

          focus


          focus

          author:entertainment    Page View:5
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In